myNEO Therapeutics is a distinguished biopharmaceutical powerhouse, dedicated to pioneer breakthrough immunotherapies to fight cancer. myNEO Therapeutics is leveraging its ImmunoEngine discovery platform to tap into novel promising tumor targets found in the dark genome – named camyotopes™ – which have the potential to unlock immunotherapy for large patient populations who currently do not respond.
 
In parallel, the service angle of myNEO Therapeutics, myNEO Intelligence, assists biopharma companies in transforming their decision-making process from trial & error to data-driven decisions using an AI-powered platform. Deriving insights from its expansive library of clinical and molecular data, myNEO Intelligence maps the molecular profiling of cancer patients at an individual level and then correlates the different data points to make data-driven decisions across the drug development life cycle. myNEO Intelligence can identify novel targets and biomarkers, prioritize drug candidates and indications, stratify patient populations and predict treatment response. 

Biotechnology

Health Care

Life Sciences

Therapeutics

myNEO Therapeutics

myNEO Therapeutics' headquarters in Ghent, Belgium

Cedric Bogaert

Sofie Pontzeele

Lore van Oudenhove

Bert Coessens

Bruno Fant

Lien Lybaert

Description

People (7)